Global assembling of Academicians, Researchers, Scholars & Industry to disseminate and exchange information at 100+ Allied Academies Conferences
The humongous success as well as the thunderous and overwhelming responses got for our previous conference has paved way for Parkinson's 2019 Organizing Committee to host the “2nd International Conference on Parkinson's, Huntington's & Movement Disorders” which is going to be held during September 27-28, 2020 as Webinar.
This year with a refreshing theme as Systematic Approaches and Progressive Therapies to treat Parkinson’s and Movement Disorders to underpin the wide range of professionals in the field of neuroscience, neurology and neurosurgery.
Parkinson's 2020 is your best opportunity to reach the largest assemblage of participants around the globe. Join, conduct presentations, exchange information and connect with the current eminent and potential scientists to explore more on neurosurgery, central nervous system, neuropharmacology and neurodegenerative disorders, make an impact with new innovations, developments and receive name recognition and certificates signed by our world-class eminent organizing committee at this two days event. World-renowned speakers, the most advanced and recent techniques, developments and the newest updates in Neurology and the Neurological Disorders are hallmarks at this conference.
Join us the exclusive Parkinson's 2020, the unique convention to bring together worldwide distinguished industrialists and academicians in the field of Neuroscience, Neurology, Neurosurgery, Neurological Disorders, Neurodegenerative disorders, Novel Therapeutics, Neuro-physiotherapy, Nanomedicine, Neuropharmacology, Nursing and more.
Meet and Explore at Edinburgh, Scotland!
Regards
Organizing Committee
Parkinson's 2020
Parkinson's 2020 welcomes attendees, presenters, and exhibitors from all over the world to Edinburgh. We are delighted to invite you to attend and register for our upcoming “4th International Conference on Parkinson's, Huntington's & Movement Disorders” which is going to be held during September 27-28, 2020 as Webinar.
Parkinson's 2020 has been designed in an interdisciplinary manner with a multitude of tracks to choose from every segment and provides you with a unique opportunity to meet up with peers from both industry and academia and establish scientific network between them. We cordially invite all concerned people to come to join us at our event and make it successful by your participation.
The conference will be organized around the Theme ‘Systematic Approaches and Progressive Therapies to treat Parkinson's and Movement disorders’. Our goal is to deliver an outstanding program that covers the entire spectrum of research &innovations in Neurology, care and share the cross-cultural experiences of various treatment procedures.
Parkinson's 2020 is an annual meeting of Neurological and Neurological Professionals as well as committees to discuss the future of the Neurological Disorders in terms of collaboration, structures and organizational development.
Parkinson's 2020 Highlights:
200+ Participation (40% Industry:60% Academia)
9+ Keynote Speakers
30+ Plenary Speakers
3+ Exhibitors
14 Innovative Educational Sessions
B2B Meetings
Why to attend???
With members from around the world focused on learning about Parkinson’s and Huntington’s Disorders and its advances; this is your best opportunity to reach the largest assemblage of participants from the Neurological Community. Conduct presentations, distribute information, meet with current and potential scientists, make a splash with new discoveries in the Neurological treatment and diagnosis, and receive name recognition at this 2-day event. World-renowned speakers, the most recent techniques, developments, and the newest updates in the field of Neurological disorders and its various treatments.
At Allied Group, It is our ideology to bring maximum exposure to our attendees, so we make sure the event is a blend that covers professionals such as Neurosurgeons, Scientists, Neurologists, Doctors, Professors, Diagnostic Laboratory Professionals from academia & industry making the Parkinson's 2020 Annual Meeting a perfect platform.
Session on: Parkinson’s Disease
Parkinson’s Disease is a chronic and progressive disease of the nervoussystem and it became worse over time. It is the second most common neurologicaldisorder. In ordinary Conditions, nerve cells exhibit in cerebrum and deliversa neurotransmitter called dopamine that oversees a development, feelings, andco-appointment yet because of unhealthy individual dopamine creation, hence theindividual end up with control the development ordinarily. In Germany, has alifetime prevalence of between 0.1 and 0.3% of the population.
Related: Parkinson’s Conference | Parkinson’s Congress | Parkinson’s Disorder Congress | Movement Disorder Conferences | Neuroscience Conference | Neurology Conference
Related Conferences:
6th World Congress on Parkinson’s & Huntington Disease, September 20-21, 2020 at Rome, Italy | International Congress of Parkinson's Disease and Movement Disorders, September 13-17, 2020, at Philadelphia, USA | 6th World Parkinson Congress, June 7-10, 2022 at Barcelona, Spain | 7th International Congresson Parkinsons and Movement Disorders, November 14-15, 2019 at London, UK | 29th World Congress on Neurology and Therapeutics, February 24-25, 2020at London, UK
Related Association and Societies:
American Academy of Neurology; Movement Disorders Society; The International Parkinson and Movement Disorder Society; Canadian Movement Disorders Group; UK Parkinson’s Action Network; European Neurological Society; European Parkinson’s Disease Association; Danish Movement Disorder Society; Italian Society for the study of Parkinson Disease; Extrapyramidal Diseases and Dementia; Movement Disorder Society of Australia; Parkinson’s Disease and Movement Disorders Society ofIndia; Australian Parkinson’s DiseaseSociety; Movement Disorder Society ofJapan
Session on: Epidemiology of Parkinson’s disease
Parkinson’s is one of the well-known age connected neurodegenerative disorder, in return simply to Alzheimer's disease. There areapproximately seven Million individuals affected with Parkinson’s globally.Several studies and theories are considering the danger factors and theprotecting measures for the onset of the Parkinson, though the results wereimperfect and foreseeable. The neuroepidemiology of PD is very complex withsusceptibility genes and several modifiable risk factors that can increase andothers that can mitigate risks and outcomes.
Related: Parkinson’s Conference | Parkinson’s Congress | Parkinson’s Disorder Congress | Movement Disorder Conferences | Neuroscience Conference | Neurology Conference
Related Conferences:
6th World Congress on Parkinson’s & Huntington Disease, September 20-21, 2020 at Rome, Italy | International Congress of Parkinson's Disease and Movement Disorders, September 13-17, 2020, at Philadelphia, USA | 6th World Parkinson Congress, June 7-10, 2022 at Barcelona, Spain | 7th International Congresson Parkinsons and Movement Disorders, November 14-15, 2019 at London, UK | 29th World Congress on Neurology and Therapeutics, February 24-25,2020 at London, UK
Related Association and Societies:
American Academy of Neurology; Movement Disorders Society; The International Parkinson and Movement Disorder Society; Canadian Movement Disorders Group; UK Parkinson’s Action Network; European Neurological Society; European Parkinson’s Disease Association; Danish Movement Disorder Society; Italian Society for the study of Parkinson Disease; Extrapyramidal Diseases and Dementia; Movement Disorder Society of Australia; Parkinson’s Disease and Movement Disorders Society ofIndia; Australian Parkinson’s DiseaseSociety; Movement Disorder Society ofJapan
Session on: Diagnosis of Parkinson’s Disease
The identification of PD is difficult in earlier stages, it goes on atthe end the result is not obtained. There is no direct treatment for PD andthere is no biopsy reports or scan reports that confirm the diagnosis. Atpresent, there is no cure for PD. Medication is given in 3 stages: Initialstage includes the drug called Levodopa, which increase the monoamineneurotransmitter in the brain, the second stage shows less severe PD symptomsand the third stage will help to manage the non-motor symptoms as well asdepression. Magnetic Resonance Imaging and Computed Tomogram are used by manyphysicians to find out other relating Parkinson’s diseases such asencephalitis, Tumours, Hydrocephalus. Dopamine level release and activity ofthe brain can easily detect using PET and SPECT examining.
Related: Parkinson’s Conference | Parkinson’s Congress | Parkinson’s Disorder Congress | Movement Disorder Conferences | Neuroscience Conference | Neurology Conference
Related Conferences:
6th World Congress on Parkinson’s & Huntington Disease, September 20-21, 2020 at Rome, Italy | International Congress of Parkinson's Disease and Movement Disorders, September 13-17, 2020, at Philadelphia, USA | 6th World Parkinson Congress, June 7-10, 2022 at Barcelona, Spain | 7th International Congresson Parkinsons and Movement Disorders, November 14-15, 2019 at London, UK | 29th World Congress on Neurology and Therapeutics, February 24-25,2020 at London, UK
Related Association and Societies:
American Academy of Neurology; Movement Disorders Society; The International Parkinson and Movement Disorder Society; Canadian Movement Disorders Group; UK Parkinson’s Action Network; European Neurological Society; European Parkinson’s Disease Association; Danish Movement Disorder Society; Italian Society for the study of Parkinson Disease; Extrapyramidal Diseases and Dementia; Movement Disorder Society of Australia; Parkinson’s Disease and Movement Disorders Society ofIndia; Australian Parkinson’s Disease Society; Movement Disorder Society of Japan
Session on: Insights and therapeutics: Parkinson’s disease
The introduction about Levodopa and the demonstration that dopamine loss is the key pathological feature of PD have revolutionized the field of PD therapeutics. In most cases of Parkinson’s disease, protein deposits called Lewy Bodies. It is unclear whether Lewy bodies play an important role in killing nerve cells or just part of the cells which are responsible to the Parkinson’s disease. Nearly 15 percent of people with PD have motor symptoms that are not controlled with levodopa. A group of drugs that act directly on dopaminergic reports called dopamine against is used as adjuncts to levodopa in the treatment of PD.
Related: Parkinson’s Conference | Parkinson’s Congress | Parkinson’s Disorder Congress | Movement Disorder Conferences | Neuroscience Conference | Neurology Conference
Related Conferences:
6th World Congress on Parkinson’s & Huntington Disease, September 20-21, 2020 at Rome, Italy | International Congress of Parkinson's Disease and Movement Disorders, September 13-17, 2020, at Philadelphia, USA | 6th World Parkinson Congress, June 7-10, 2022 at Barcelona, Spain | 7th International Congress on Parkinson's and Movement Disorders, November 14-15, 2019 at London, UK | 29th World Congress on Neurology and Therapeutics, February 24-25,2020 at London, UK
Related Association and Societies:
American Academy of Neurology; Movement Disorders Society; The International Parkinson and Movement Disorder Society; Canadian Movement Disorders Group; UK Parkinson’s Action Network; European Neurological Society; European Parkinson’s Disease Association; Danish Movement Disorder Society; Italian Society for the study of Parkinson Disease; Extrapyramidal Diseases and Dementia; Movement Disorder Society of Australia; Parkinson’s Disease and Movement Disorders Society of India; Australian Parkinson’s Disease Society; Movement Disorder Society of Japan
Session on: Parkinson’s Disease complications
Parkinson’s disease is not a life-threatening condition. With time, the illness will bring more problems with speech, movement, and brain functioning. Parkinson’s disease is usually accompanied by additional problems, which may be cured, and they are thinking difficulties, swallowing, depression and emotional changes, sleep difficulties, constipation, blood pressure changes, fatigue, pain, and some complications are Insomnia, Urinary Incontinence, Paraesthesia.
Related: Parkinson’s Conference | Parkinson’s Congress | Parkinson’s Disorder Congress | Movement Disorder Conferences | Neuroscience Conference | Neurology Conference
Related Conferences:
6th World Congress on Parkinson’s & Huntington Disease, September 20-21, 2020 at Rome, Italy | International Congress of Parkinson's Disease and Movement Disorders, September 13-17, 2020, at Philadelphia, USA | 6th World Parkinson Congress, June 7-10, 2022 at Barcelona, Spain | 7th International Congresson Parkinsons and Movement Disorders, November 14-15, 2019 at London, UK | 29th World Congress on Neurology and Therapeutics, February 24-25,2020 at London, UK
Related Association and Societies:
American Academy of Neurology; Movement Disorders Society; The International Parkinson and Movement Disorder Society; Canadian Movement Disorders Group; UK Parkinson’s Action Network; European Neurological Society; European Parkinson’s Disease Association; Danish Movement Disorder Society; Italian Society for the study of Parkinson Disease; Extrapyramidal Diseases and Dementia; Movement Disorder Society of Australia; Parkinson’s Disease and Movement Disorders Society ofIndia; Australian Parkinson’s DiseaseSociety; Movement Disorder Society ofJapan
Session on: Pathophysiology and Pharmacology
Parkinson’s disease is originated from the gradual loss of cells in the substantia nigral of the brain. This is mainly responsible for the assembly of neuro transmitter. Dopamine is a neurotransmitter which transmits signals between two regions of the brain to coordinate activities like the movement oflimbs. If there is a deficiency in dopamine production results in loss of coordination and end up with the symptoms of Parkinson’s Disease. The disease progresses, various areas of the brain and nervous system degenerate to boo inflicting a lot of movement disorder.
Related: Parkinson’s Conference | Parkinson’s Congress | Parkinson’s Disorder Congress | Movement Disorder Conferences | Neuroscience Conference | Neurology Conference
Related Conferences:
6th World Congress on Parkinson’s & Huntington Disease, September 20-21, 2020 at Rome, Italy | International Congress of Parkinson's Disease and Movement Disorders, September 13-17, 2020, at Philadelphia, USA | 6th World Parkinson Congress, June 7-10, 2022 at Barcelona, Spain | 7th International Congress on Parkinson's and Movement Disorders, November 14-15, 2019 at London, UK | 29th World Congress on Neurology and Therapeutics, February 24-25,2020 at London, UK
Related Association and Societies:
American Academy of Neurology; Movement Disorders Society; The International Parkinson and Movement Disorder Society; Canadian Movement Disorders Group; UK Parkinson’s Action Network; European Neurological Society; European Parkinson’s Disease Association; Danish Movement Disorder Society; Italian Society for the study of Parkinson Disease; Extrapyramidal Diseases and Dementia; Movement Disorder Society of Australia; Parkinson’s Disease and Movement Disorders Society of India; Australian Parkinson’s Disease Society; Movement Disorder Society of Japan
Session on: Clinical Trials in Parkinsonism
To develop a drug or treatment for Parkinson’s disease observational study is being conducted by a scientist in a laboratory to provide patients with a better life. Clinical trials are performed to slow down the rate of suffering and reduce the symptoms. There is no cure for PD as far, butresearchers improved more treatment. Trails help to reduce the risk factors. Trail sari the best way to find out whether a new treatment is safe, is a benefit to patients, is more effective, is that improving the quality of life with PD
Clinical research is an expensive process which requires strong financial support. This comes from a range of sponsors including thepharmaceutical industries, Governments, Researchers, and Organizations.
Related: Parkinson’s Conference | Parkinson’s Congress | Parkinson’s Disorder Congress | Movement Disorder Conferences | Neuroscience Conference | Neurology Conference
Related Conferences:
6th World Congress on Parkinson’s & Huntington Disease, September 20-21,2020 at Rome, Italy | International Congress of Parkinson's Disease and Movement Disorders, September 13-17,2020, at Philadelphia, USA | 6th World Parkinson Congress, June 7-10, 2022 atBarcelona, Spain | 7th International Congress on Parkinsons and Movement Disorders, November 14-15,2019 at London, UK | 29th World Congress on Neurology and Therapeutics, February 24-25, 2020 at London, UK
Related Association and Societies:
American Academy of Neurology; Movement Disorders Society; The International Parkinson and Movement Disorder Society; Canadian Movement Disorders Group; UK Parkinson’s Action Network; European Neurological Society; European Parkinson’s Disease Association; Danish Movement Disorder Society; Italian Society for the study of Parkinson Disease; Extrapyramidal Diseases and Dementia; Movement Disorder Society of Australia; Parkinson’s Disease and Movement Disorders Society of India; Australian Parkinson’s Disease Society; Movement Disorder Society of Japan
Session on: Free Radicals and Aging in Parkinson’s
Free radicles have both beneficial and baleful effect on human body parts. Oxidative stress is known to cause many neurological disorders such as Alzheimer’s, Parkinson’s and Amyotrophic Lateral Sclerosis. With oldness, there is a typical failure of the dopamine-producing neurons. In some of the rare situation’s symptoms are seen in children and terms is referred to as Juvenile Parkinsonism.
Related: Parkinson’s Conference | Parkinson’s Congress | Parkinson’s Disorder Congress | Movement Disorder Conferences | Neuroscience Conference | Neurology Conference
Related Conferences:
6th World Congress on Parkinson’s & Huntington Disease, September 20-21,2020 at Rome, Italy | International Congress of Parkinson's Disease and Movement Disorders, September 13-17,2020, at Philadelphia, USA | 6th World Parkinson Congress, June 7-10, 2022 at Barcelona, Spain | 7th International Congress on Parkinson's and Movement Disorders, November 14-15,2019 at London, UK | 29th World Congress on Neurology and Therapeutics, February 24-25, 2020 at London, UK
Related Association and Societies:
American Academy of Neurology; Movement Disorders Society; The International Parkinson and Movement Disorder Society; Canadian Movement Disorders Group; UK Parkinson’s Action Network; European Neurological Society; European Parkinson’s Disease Association; Danish Movement Disorder Society; Italian Society for the study of Parkinson Disease; Extrapyramidal Diseases and Dementia; Movement Disorder Society of Australia; Parkinson’s Disease and Movement Disorders Society of India; Australian Parkinson’s Disease Society; Movement Disorder Society of Japan
Session on: Managing life with Parkinson’s disease
It is important to develop a PD management plan because it is a chronic disease. The individual should get practiced maintaining the stress levels and depression by daily communicating with close people, friends, colleagues. Patients can improve life by following Instructions given by the counsellor. Managing life with PD includes building a healthcare team with proper Doctors, proper intake of medications, exercises, nutritional drink, and proper sleep.
Related: Parkinson’s Conference | Parkinson’s Congress | Parkinson’s Disorder Congress | Movement Disorder Conferences | Neuroscience Conference | Neurology Conference
Related Conferences:
6th World Congress on Parkinson’s & Huntington Disease, September 20-21,2020 at Rome, Italy | International Congress of Parkinson's Disease and Movement Disorders, September 13-17,2020, at Philadelphia, USA | 6th World Parkinson Congress, June 7-10, 2022 at Barcelona, Spain | 7th International Congress on Parkinson's and Movement Disorders, November 14-15,2019 at London, UK | 29th World Congress on Neurology and Therapeutics, February 24-25, 2020 at London, UK
Related Association and Societies:
American Academy of Neurology; Movement Disorders Society; The International Parkinson and Movement Disorder Society; Canadian Movement Disorders Group; UK Parkinson’s Action Network; European Neurological Society; European Parkinson’s Disease Association; Danish Movement Disorder Society; Italian Society for the study of Parkinson Disease; Extrapyramidal Diseases and Dementia; Movement Disorder Society of Australia; Parkinson’s Disease and Movement Disorders Society of India; Australian Parkinson’s Disease Society; Movement Disorder Society of Japan
Session on: Risk Factors of Parkinson’s Disease
Risk factors for the PD mainly depend on age, hereditary, sex and exposure to toxins. The causes of the diseases are believed to be either genetic or environmental. Symptoms and progression of disease will not be the same among the suffering individuals but people with Parkinson’s are at higher rate of developing related risks. Parkinson’s disease has a chance of creating mental ailment which can be mild or serious. It includes cognition, mood, behavior which are considered as major impairment when compared to normal populational. The common mood swings seen in the patients are despair, eagerness, indifference Melanoma, Neurogenic, Orthostatic Hypotension, Executive dysfunction, Orthostatic hypertension. Now a day’s Head Injury and Gene variation are in addition to an element of PD.
Related: Parkinson’s Conference | Parkinson’s Congress | Parkinson’s Disorder Congress | Movement Disorder Conferences | Neuroscience Conference | Neurology Conference
Related Conferences:
6th World Congress on Parkinson’s & Huntington Disease, September 20-21,2020 at Rome, Italy | International Congress of Parkinson's Disease and Movement Disorders, September 13-17,2020, at Philadelphia, USA | 6th World Parkinson Congress, June 7-10, 2022 at Barcelona, Spain | 7th International Congress on Parkinson's and Movement Disorders, November 14-15,2019 at London, UK | 29th World Congress on Neurology and Therapeutics, February 24-25, 2020 at London, UK
Related Association and Societies:
American Academy of Neurology; Movement Disorders Society; The International Parkinson and Movement Disorder Society; Canadian Movement Disorders Group; UK Parkinson’s Action Network; European Neurological Society; European Parkinson’s Disease Association; Danish Movement Disorder Society; Italian Society for the study of Parkinson Disease; Extrapyramidal Diseases and Dementia; Movement Disorder Society of Australia; Parkinson’s Disease and Movement Disorders Society of India; Australian Parkinson’s Disease Society; Movement Disorder Society of Japan
Session on: Neurodegenerative Diseases
Neurodegeneration is the progressive loss of structure or function of neurons, including the death of neurons. Many neurodegenerative diseases –including Parkinson's disease, Alzheimer's disease, and Huntington's disease and amyotrophic lateral sclerosis, – occur as a result of neurodegenerative processes. The greatest risk factor for neurodegenerative diseases is aging. Mitochondrial DNA mutations as well as oxidative stress both contribute to aging. Many of these diseases are late onset, meaning there is some factor that changes as a person ages for each disease. One constant factories that in each disease, neurons gradually lose function as the disease progresses with age. It has been proposed that DNA damage accumulation provides the underlying causative link between aging and neurodegenerative disease.
Related: Parkinson’s Conference | Parkinson’s Congress | Parkinson’s Disorder Congress | Movement Disorder Conferences | Neuroscience Conference | Neurology Conference
Related Conferences:
6th World Congress on Parkinson’s & Huntington Disease, September 20-21,2020 at Rome, Italy | International Congress of Parkinson's Disease and Movement Disorders, September 13-17,2020, at Philadelphia, USA | 6th World Parkinson Congress, June 7-10, 2022 at Barcelona, Spain | 7th International Congress on Parkinson's and Movement Disorders, November 14-15,2019 at London, UK | 29th World Congress on Neurology and Therapeutics, February 24-25, 2020 at London, UK
Related Association and Societies:
American Academy of Neurology; Movement Disorders Society; The International Parkinson and Movement Disorder Society; Canadian Movement Disorders Group; UK Parkinson’s Action Network; European Neurological Society; European Parkinson’s Disease Association; Danish Movement Disorder Society; Italian Society for the study of Parkinson Disease; Extrapyramidal Diseases and Dementia; Movement Disorder Society of Australia; Parkinson’s Disease and Movement Disorders Society of India; Australian Parkinson’s Disease Society; Movement Disorder Society of Japan
Session on: Huntington’s Disease
Huntington’s disease (HD) is a fatal genetic disorder usually inherited from Parents and often many describe the symptoms of HD as having Parkinson’s and Alzheimer’s disease simultaneously. Symptoms usually appear between the ages of 30 to 50 and worsen over a 10 to 25 every year. The weak people tend to have pneumonia, Heart failure, and other complications. Every person who inherits the expanded HD gene will eventually develop the Huntington disease. Over a period, HD affects the individual’s ability to reason, walk and speak. In approximately 10% of cases have HD in children or adolescents. The symptoms of Juvenile HD are somewhat different than adult-onset HD and it includes Stiffness or awkward walking, increased clumsiness and changes in speech. The ability of learning skills may tend to decline, and the child may lose skills.
Related: Parkinson’s Conference | Parkinson’s Congress | Parkinson’s Disorder Congress | Movement Disorder Conferences | Neuroscience Conference | Neurology Conference
Related Conferences:
6th World Congress on Parkinson’s & Huntington Disease, September 20-21,2020 at Rome, Italy | International Congress of Parkinson's Disease and Movement Disorders, September 13-17,2020, at Philadelphia, USA | 6th World Parkinson Congress, June 7-10, 2022 at Barcelona, Spain | 7th International Congress on Parkinson's and Movement Disorders, November 14-15,2019 at London, UK | 29th World Congress on Neurology and Therapeutics, February 24-25, 2020 at London, UK
Related Association and Societies:
American Academy of Neurology; Movement Disorders Society; The International Parkinson and Movement Disorder Society; Canadian Movement Disorders Group; UK Parkinson’s Action Network; European Neurological Society; European Parkinson’s Disease Association; Danish Movement Disorder Society; Italian Society for the study of Parkinson Disease; Extrapyramidal Diseases and Dementia; Movement Disorder Society of Australia; Parkinson’s Disease and Movement Disorders Society of India; Australian Parkinson’s Disease Society; Movement Disorder Society of Japan
Session on: Bradykinesia
According to studies more than men, women were mostly affected by Bradykinesia. It is a reduced pace in bodily movements of a person. Parkinson’s has four key symptoms, in that Bradykinesia is one among them. Parkinson’s is also called "Idiopathic parkinsonism", meaning parkinsonism with nonidentifiable cause.
Related: Parkinson’s Conference | Parkinson’s Congress | Parkinson’s Disorder Congress | Movement Disorder Conferences | Neuroscience Conference | Neurology Conference
Related Conferences:
6th World Congress on Parkinson’s & Huntington Disease, September 20-21,2020 at Rome, Italy | International Congress of Parkinson's Disease and Movement Disorders, September 13-17,2020, at Philadelphia, USA | 6th World Parkinson Congress, June 7-10, 2022 at Barcelona, Spain | 7th International Congress on Parkinson's and Movement Disorders, November 14-15,2019 at London, UK | 29th World Congress on Neurology and Therapeutics, February 24-25, 2020 at London, UK
Related Association and Societies:
American Academy of Neurology; Movement Disorders Society; The International Parkinson and Movement Disorder Society; Canadian Movement Disorders Group; UK Parkinson’s Action Network; European Neurological Society; European Parkinson’s Disease Association; Danish Movement Disorder Society; Italian Society for the study of Parkinson Disease; Extrapyramidal Diseases and Dementia; Movement Disorder Society of Australia; Parkinson’s Disease and Movement Disorders Society of India; Australian Parkinson’s Disease Society; Movement Disorder Society of Japan
Session on: Ataxia
Ataxia is a degenerative disease of the nervous system. Many symptoms of Ataxia can mimic those of being drunk - slurred speech, stumbling, falling, and incoordination. All are related to degeneration of the part of the brain ,called the cerebellum that is responsible for coordinating movement. Ataxia isa disease that affects people of all ages. Age of symptom-onset canary widely, from childhood to late adulthood. Complications from the disease are serious, oftentimes debilitating, and can be life-shortening. Ataxia is anumbrella term used to classify a group of diseases that include: Ataxia Telangiectasia, Episodic Ataxia, Friedreich’s Ataxia, Multiple System Atrophy, Spinocerebellar Ataxia, Sporadic Ataxia.
Related: Parkinson’s Conference | Parkinson’s Congress | Parkinson’s Disorder Congress | Movement Disorder Conferences | Neuroscience Conference | Neurology Conference
Related Conferences:
6th World Congress on Parkinson’s & Huntington Disease, September 20-21,2020 at Rome, Italy | International Congress of Parkinson's Disease and Movement Disorders, September 13-17,2020, at Philadelphia, USA | 6th World Parkinson Congress, June 7-10, 2022 at Barcelona, Spain | 7th International Congress on Parkinson's and Movement Disorders, November 14-15,2019 at London, UK | 29th World Congress on Neurology and Therapeutics, February 24-25, 2020 at London, UK
Related Association and Societies:
American Academy of Neurology; Movement Disorders Society; The International Parkinson and Movement Disorder Society; Canadian Movement Disorders Group; UK Parkinson’s Action Network; European Neurological Society; European Parkinson’s Disease Association; Danish Movement Disorder Society; Italian Society for the study of Parkinson Disease; Extrapyramidal Diseases and Dementia; Movement Disorder Society of Australia; Parkinson’s Disease and Movement Disorders Society of India; Australian Parkinson’s Disease Society; Movement Disorder Society of Japan
Session on: Aphasia
Aphasia is an inability to comprehend or formulate language because of damage to specific brain regions. This damage is typically caused by cerebral vascular accident (stroke), or head trauma; however, these are not the only possible causes. In Aphasia, a person's speech or language will be significantly impaired in one (or several) of the four communication modalities following acquired by brain injury or have significant decline over a short time period. The four communication modalities are auditory comprehension, verbal expression, reading and writing, and functional communication.
Related: Parkinson’s Conference | Parkinson’s Congress | Parkinson’s Disorder Congress | Movement Disorder Conferences | Neuroscience Conference | Neurology Conference
Related Conferences:
6th World Congress on Parkinson’s & Huntington Disease, September 20-21,2020 at Rome, Italy | International Congress of Parkinson's Disease and Movement Disorders, September 13-17,2020, at Philadelphia, USA | 6th World Parkinson Congress, June 7-10, 2022 at Barcelona, Spain | 7th International Congress on Parkinson's and Movement Disorders, November 14-15,2019 at London, UK | 29th World Congress on Neurology and Therapeutics, February 24-25, 2020 at London, UK
Related Association and Societies:
American Academy of Neurology; Movement Disorders Society; The International Parkinson and Movement Disorder Society; Canadian Movement Disorders Group; UK Parkinson’s Action Network; European Neurological Society; European Parkinson’s Disease Association; Danish Movement Disorder Society; Italian Society for the study of Parkinson Disease; Extrapyramidal Diseases and Dementia; Movement Disorder Society of Australia; Parkinson’s Disease and Movement Disorders Society of India; Australian Parkinson’s Disease Society; Movement Disorder Society of Japan
Session on: Alzheimer’s Disease & Dementia
Alzheimer’s is caused by cerebrum cell demise and it is a neurological issue in which the demise of cerebrum cells causes memory misfortune and intellectual decrease. Dementia is a general form term for a decline in ability severe enough to interface with daily life. Alzheimer’s is the most common type of dementia. Memory loss is an example. The disease progress in different stages: Early, Moderate and Advanced stages. Early stage is Tremor, it is the first symptom. As it continues it will lead to Dementia in few cases. Some of the complications include Dementia of Alzheimer’s Disease, Treatment of Alzheimer’s Disease, Stroke related Dementia, Young onset Dementia.
Related: Parkinson’s Conference | Parkinson’s Congress | Parkinson’s Disorder Congress | Movement Disorder Conferences | Neuroscience Conference | Neurology Conference
Related Conferences:
6th World Congress on Parkinson’s & Huntington Disease, September 20-21,2020 at Rome, Italy | International Congress of Parkinson's Disease and Movement Disorders, September 13-17,2020, at Philadelphia, USA | 6th World Parkinson Congress, June 7-10, 2022 atBarcelona, Spain | 7th International Congress on Parkinson's and Movement Disorders, November 14-15,2019 at London, UK | 29th World Congress on Neurology and Therapeutics, February 24-25, 2020 at London, UK
Related Association and Societies:
American Academy of Neurology; Movement Disorders Society; The International Parkinson and Movement Disorder Society; Canadian Movement Disorders Group; UK Parkinson’s Action Network; European Neurological Society; European Parkinson’s Disease Association; Danish Movement Disorder Society; Italian Society for the study of Parkinson Disease; Extrapyramidal Diseases and Dementia; Movement Disorder Society of Australia; Parkinson’s Disease and Movement Disorders Society of India; Australian Parkinson’s Disease Society; Movement Disorder Society of Japan
Session on: Pediatric Movement disorders
It is a moderately new and developing field of child neurology. There are many genetic diseases which cause secondary movement disorder in childhood. Propels in pediatric movement disorder have been made by solidifying movement disorder definitions, growing the range of phenotypes, understanding genetic reasons for movement disorders, and thoroughly assessing treatment adequacy for normal movement disorder. The central nervous system typically implicated in disorders of movements are the basal and frontal cortex.
Related: Parkinson’s Conference | Parkinson’s Congress | Parkinson’s Disorder Congress | Movement Disorder Conferences | Neuroscience Conference | Neurology Conference
Related Conferences:
6th World Congress on Parkinson’s & Huntington Disease, September 20-21,2020 at Rome, Italy | International Congress of Parkinson's Disease and Movement Disorders, September 13-17,2020, at Philadelphia, USA | 6th World Parkinson Congress, June 7-10, 2022 at Barcelona, Spain | 7th International Congress on Parkinson's and Movement Disorders, November 14-15,2019 at London, UK | 29th World Congress on Neurology and Therapeutics, February 24-25, 2020 at London, UK
Related Association and Societies:
American Academy of Neurology; Movement Disorders Society; The International Parkinson and Movement Disorder Society; Canadian Movement Disorders Group; UK Parkinson’s Action Network; European Neurological Society; European Parkinson’s Disease Association; Danish Movement Disorder Society; Italian Society for the study of Parkinson Disease; Extrapyramidal Diseases and Dementia; Movement Disorder Society of Australia; Parkinson’s Disease and Movement Disorders Society of India; Australian Parkinson’s Disease Society; Movement Disorder Society of Japan
Session on: Neuromuscular Disorders and Neural transplantation
Neurons are responsible for communication when they cannot produce signals communication between nervous system breaks and result in neuromuscular disorders. Some of them are ALS, Multiple sclerosis, Alzheimer’s disease, Spinal Muscular Atrophy. Neural transplantation is the transplantation of nerve cells, tissues into the brain and spinal cord. The cell replacement for PD is based on two hypothesis- firstly the early symptoms of PD are dependent on the loss of the dopaminergic neurons in the nigrostriatal pathways and secondly the dopaminergic neurons are gathered into dopamine deficient striatum can replace those neurons which has been lost during the disease process and can reverse some extent of the major symptoms of PD. Some of the therapies are Neural Grafting, Transplantation therapy, Cell Transplantation, Rebuilding of Dopamine Circuit
Related: Parkinson’s Conference | Parkinson’s Congress | Parkinson’s Disorder Congress | Movement Disorder Conferences | Neuroscience Conference | Neurology Conference
Related Conferences:
6th World Congress on Parkinson’s & Huntington Disease, September 20-21,2020 at Rome, Italy | International Congress of Parkinson's Disease and Movement Disorders, September 13-17,2020, at Philadelphia, USA | 6th World Parkinson Congress, June 7-10, 2022 at Barcelona, Spain | 7th International Congress on Parkinson's and Movement Disorders, November 14-15, 2019at London, UK | 29th World Congress on Neurology and Therapeutics, February 24-25, 2020 at London, UK
Related Association and Societies:
American Academy of Neurology; Movement Disorders Society; The International Parkinson and Movement Disorder Society; Canadian Movement Disorders Group; UK Parkinson’s Action Network; European Neurological Society; European Parkinson’s Disease Association; Danish Movement Disorder Society; Italian Society for the study of Parkinson Disease; Extrapyramidal Diseases and Dementia; Movement Disorder Society of Australia; Parkinson’s Disease and Movement Disorders Society of India; Australian Parkinson’s Disease Society; Movement Disorder Society of Japan
Session on: Neurosurgery
Presently Deep brain stimulator is widely recommended for improving people suffering from Parkinson’s disease. There will be no effect by using DBS to healthy brain tissue by terminating nerve cells. Instead of that, the procedure blocks electrical signals from targeted areas in the brain.
Related: Parkinson’s Conference | Parkinson’s Congress | Parkinson’s Disorder Congress | Movement Disorder Conferences | Neuroscience Conference | Neurology Conference
Related Conferences:
6th World Congress on Parkinson’s & Huntington Disease, September 20-21,2020 at Rome, Italy | International Congress of Parkinson's Disease and Movement Disorders, September 13-17,2020, at Philadelphia, USA | 6th World Parkinson Congress, June 7-10, 2022 at Barcelona, Spain | 7th International Congress on Parkinson's and Movement Disorders, November 14-15,2019 at London, UK | 29th World Congress on Neurology and Therapeutics, February 24-25, 2020 at London, UK
Related Association and Societies:
American Academy of Neurology; Movement Disorders Society; The International Parkinson and Movement Disorder Society; Canadian Movement Disorders Group; UK Parkinson’s Action Network; European Neurological Society; European Parkinson’s Disease Association; Danish Movement Disorder Society; Italian Society for the study of Parkinson Disease; Extrapyramidal Diseases and Dementia; Movement Disorder Society of Australia; Parkinson’s Disease and Movement Disorders Society of India; Australian Parkinson’s Disease Society; Movement Disorder Society of Japan
Session on: Novel Therapeutics
The most used drug for treating Parkinson’s disease is Levodopa which has a higher frequency to develop motor fluctuations and results in L-do pain induced dyskinesia (LID). Researchers propose novel ideas to treat Parkinson’s disease to decrease the risk of causing side effects, the frequency of dyskinesia, to treat cognitive disorders such as Anxiety and depression.
Related: Parkinson’s Conference | Parkinson’s Congress | Parkinson’s Disorder Congress | Movement Disorder Conferences | Neuroscience Conference | Neurology Conference
Related Conferences:
6th World Congress on Parkinson’s & Huntington Disease, September 20-21,2020 at Rome, Italy | International Congress of Parkinson's Disease and Movement Disorders, September 13-17,2020, at Philadelphia, USA | 6th World Parkinson Congress, June 7-10, 2022 at Barcelona, Spain | 7th International Congress on Parkinson's and Movement Disorders, November 14-15,2019 at London, UK | 29th World Congress on Neurology and Therapeutics, February 24-25, 2020 at London, UK
Related Association and Societies:
American Academy of Neurology; Movement Disorders Society; The International Parkinson and Movement Disorder Society; Canadian Movement Disorders Group; UK Parkinson’s Action Network; European Neurological Society; European Parkinson’s Disease Association; Danish Movement Disorder Society; Italian Society for the study of Parkinson Disease; Extrapyramidal Diseases and Dementia; Movement Disorder Society of Australia; Parkinson’s Disease and Movement Disorders Society of India; Australian Parkinson’s Disease Society; Movement Disorder Society of Japan
Parkinson’s disease market is set to expand from $2.2 billion in 2014 to $3.3 billion by 2022, at a moderate Compound Annual Growth Rate (CAGR) of 5.8 percent, game-changing treatments will not be available for the future, according to business intelligence provider GBI Research. There are approximately 10 million individuals experiencing Parkinson's infection all around the world. Parkinson's as far it has a higher recurrence in the created nations.
In Worldwide, it's estimated that 6.3 million people have PD with no differentiation for race and culture. The age of onset is usually over 60-65, but it is estimated that one in ten are diagnosed before the age of 50, and it can affect people in their 40’s and younger.
According to available statistics, 2 million people in Europe have Parkinson’s, which approximates to:
260,000 in Germany
200,000 in Italy
150,000 in Spain
120,000 in UK
117,000 in France.
PD makes the second most common neurodegenerative disorder, that is it equates to a rate of more than 1 per 1000 people in Europe.
It is difficult to tell how common Huntington’s Disease HD is in a population across the world. In Western Countries, it’s estimated that about five to nine people per 100,000 are affected by HD. A high population of HD has also been found in the Lake Maracaibo region of Venezuela where the prevalence of HD is about 700 per 100,000.
For more details please visit: parkinsons.alliedacademies.com
Conference Highlights:
Parkinson’s Disease
Epidemiology of Parkinson’s disease
Diagnosis of Parkinson's disease
Insights and therapeutics: Parkinson’s disease
Parkinson's disease Complications
Pathophysiology and Pharmacology
Clinical trials in parkinsonism
Free radicals and aging in parkinsonism
Managing life with Parkinson's disease
Risk factors of Parkinson’s disease
Huntington’s Disease
Bradykinesia
Alzheimer’s disease and Dementia
Pediatric movement disorder
Neuromuscular Disorder
Neurosurgery
Novel Therapeutics
Target Audience
Neurologists, Psychiatrists, Psychologists, Neurosurgeon, Director, Industries, Delegates, Clinical Specialists, Physicians, Neuroscientists, Community members, Lectures and Students from various Academics, Professors, Researchers, Scientists, Therapists.
Major Associations around the Globe
National Parkinson Foundation
American Parkinson Disease Association (APDA)
Parkinson’s disease Foundation
Movement Disorder Society of Australia
Parkinson's Unity Walk
Movement Disorder Society of Japan
Moroccan Neurological Society Movement Disorders Group
Italian Society for the Study of Parkinson Disease, Extrapyramidal Diseases, and Dementia
Ecuador Movement Disorders Group
Austrian Parkinson's Disease Society
Danish Movement Disorder Society
Top universities500 globally working in the field of Parkinson's Disease
University of Bath
The University of Queensland
University of Bristol
University of Cambridge
The Imperial College of Science and Medicine
Duke University
University of Milan
Karolinska Institute
University of Hamburg
The University of Edinburgh
University of Munich
University of Rochester
University of Zurich
Leiden University
University of Bristol
University of Helsinki
Uppsala University
University of Freiburg
University of Frankfurt
All accepted abstracts will be published in respective Allied Academies Journals.
Abstracts will be provided with Digital Object Identifier by
